GlassScriptPhysician profile
Andrew M Singer
NPI 1255420188
$6,444.96
in general payments reported to CMS, 2019-2025
28 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,033 · 2020: $146 · 2021: $247 · 2022: $1,227 · 2023: $1,368 · 2024: $1,137 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,721 · Education: $70.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,721.23 |
| Education | $70.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,312.04 | 2019-2025 | Dupixent |
| Csl Behring | $936.90 | 2019-2025 | Hizentra, Haegarda |
| Astrazeneca Pharmaceuticals LP | $611.86 | 2019-2025 | Fasenra, Tezspire |
| Genzyme Corporation | $555.63 | 2019-2025 | |
| Glaxosmithkline, LLC. | $474.24 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genentech USA, INC. | $387.86 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $375.50 | 2020-2025 | Cuvitru, Gammagard |
| Pfizer INC. | $259.74 | 2019-2025 | |
| Hospira, INC. | $249.21 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $232.08 | 2019-2025 | |
| Grifols USA, LLC | $171.11 | 2019-2025 | Xembify |
| Ars Pharmaceuticals Operations, INC. | $129.35 | 2025 | Neffy |
| Kaleo, INC. | $110.23 | 2019-2024 | Auvi-Q |
| Optinose US, INC. | $87.26 | 2024-2025 | |
| Blueprint Medicines Corporation | $79.80 | 2022-2024 | Ayvakit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $78.25 | 2022 | |
| Pharming Healthcare, INC. | $66.49 | 2023-2024 | Ruconest |
| Octapharma USA, INC. | $48.97 | 2022-2023 | Cutaquig |
| Abbvie INC. | $47.92 | 2025 | |
| Aimmune Therapeutics, INC. | $38.18 | 2022 | |
| Phadia US INC. | $36.09 | 2019-2020 | |
| Amgen INC. | $34.14 | 2023-2025 | Tezspire |
| Shire North American Group INC | $30.69 | 2019 | |
| Biocryst US Sales Co., LLC | $22.76 | 2023 | Orladeyo |
| Hikma Pharmaceuticals USA | $20.41 | 2025 | Ryaltris |
| Cycle Pharmaceuticals INC | $18.63 | 2024 | Sajazir |
| X4 Pharmaceuticals, INC. | $18.54 | 2024 | Xolremdi |
| Organon LLC | $11.08 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Singer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.